Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $191.34M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.20M
Average 0.48M
CGEN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Compugen Ltd.NASDAQ: CGEN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $2.43M fell 3.0% year over year, ahead of the -6.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 10.0% from the prior quarter. Over 3 fiscal years it compounded at -5.7% a year.
Context
- Selling, general & admin amounted to 13.0% of revenue in FY2025, down 23.0 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $9.64M (+2.2%) for the fiscal year ending Dec 2026, a step up from the -5.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.43M+10.0% QoQ
- Last fiscal yearDec 2025
- $9.43M-5.8% YoY
- LTMMar 2026
- $9.36M-6.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.43M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- -5.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.43M | -5.8% |
| FY2024 | 2024-12-31 | 10.02M | +0.4% |
| FY2023 | 2023-12-31 | 9.98M | -11.3% |
| FY2022 | 2022-12-31 | 11.25M | -3.8% |
| FY2021 | 2021-12-31 | 11.7M | — |
Selling, General & Admin vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.3% is the 7th highest of 9, against a peer median of -4.1%.
- Selling, general & admin amounts to 12.9% of revenue for CGEN, versus a peer median of 599.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $63.26M USD | +90.6% | +41.6% | 360.3% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| FY2025 | €11M EUR | -7.8% | -8.7% | 394.7% | |
| LTM Mar 2026 | $9.69M USD | +36.8% | +16.2% | — | |
| LTM Mar 2026 | $9.36M USD | -6.3% | -5.7% | 12.9% | |
| Peer median (excluding CGEN) | — | -4.1% | -7.7% | 599.8% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | 680K | 975K | 2M | 7.93M | 9.25M |
| Gross Profit | 5.32M | 6.53M | 31.46M | 19.93M | 63.51M |
| Gross Margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Research & Development | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
| Selling, General & Admin | 11.7M | 11.25M | 9.98M | 10.02M | 9.43M |
| Operating Expenses | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| EBITDA | (33.72M) | (33.13M) | (9.28M) | (9.19M) | 35.87M |
| EBITDA Margin | -562.0% | -441.7% | -27.7% | -33.0% | 49.3% |
| Operating Income | (35.07M) | (35.37M) | (12.99M) | (14.89M) | 31.33M |
| Operating Margin | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Interest Income | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
| Interest Expense | 25K | 27K | 31K | 34K | 0 |
| Other Income / Expenses | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
| Income Before Tax | (34.2M) | (33.64M) | (9.78M) | (9.71M) | 35.4M |
| Pre-Tax Margin | -570.0% | -448.5% | -29.2% | -34.8% | 48.6% |
| Income Tax Expense | 0 | 58K | 8.97M | 4.52M | 54K |
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Net Margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (Basic) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| EPS (Diluted) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| Weighted Avg Shares | 84.2M | 86.56M | 87.63M | 89.53M | 93.43M |
| Weighted Avg Shares (Diluted) | 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$2.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.